# Lineage Cell Therapeutics (LCTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/LCTX
## Company Profile
- Ticker: LCTX
- Exchange: AMEX
- Sector: Biopharma
- Location: United States
- Tags: Ophthalmology
## Stock Data
- Close: 1.1 USD
- Market cap: 301650936.95 USD
- Last updated: 2026-08-12
## Business Overview
### Pluripotent Cell Therapy Company
Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform.
### OpRegen
RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic atrophy.
### Wholly Owned Pipeline
Lineage is applying its platform to oligodendrocyte, auditory neuron, and corneal endothelial cell programs, including the newly launched COR1 program.
### Manufacturing Model
The company differentiates and expands specific cell types from pluripotent master cell banks, supporting consistent and scalable production.
## Why The Stock Is Moving

As of Aug 12, 2026, LCTX closed down 1.79% at $1.10. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-06 20:01 EST — [Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-second-quarter-2026-financial-results-and-prov-164fe544) — Source: Lineage Cell Therapeutics
- 2026-07-30 12:00 EST — [Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-report-second-quarter-2026-financial-results-and-pr-8da697b1) — Source: Lineage Cell Therapeutics
- 2026-07-13 12:00 EST — [Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease](https://biopharmsignal.com/news/LCTX/lineage-provides-update-on-cor1-cell-therapy-program-for-corneal-endothelial-dis-fe72f64a) — Source: Lineage Cell Therapeutics
- 2026-07-06 12:00 EST — [Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-present-at-b-riley-securities-2026-mind-muscle-visi-93d042e3) — Source: Lineage Cell Therapeutics
- 2026-05-12 20:01 EST — [Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Lineage Cell Therapeutics